8-K filing — Zenas BioPharma, Inc. (ZBIO)
Filed: 2026-11-05 AccNo: 0001104659-26-123035 Size: 282 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Corporate Updates
Zenas BioPharma announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs, including the ongoing Phase 1 trial of ZB021.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zenas BioPharma Outlines R&D Strategy for Obexelimab and ZB021
Zenas BioPharma held an R&D event on October 30, 2026, to detail development plans for its lead candidate obexelimab and its oral IL-17 inhibitor ZB021.
Morgan Stanley Initiates Coverage of Zenas BioPharma with Hold Rating
Morgan Stanley analyst Chris Yu has initiated coverage on Zenas BioPharma, Inc. with a 'Hold' rating and a price target of $32.
InnoCare Pharma Reports Continued Progress in Collaboration with Zenas BioPharma
InnoCare Pharma's third quarter 2026 business update highlights the ongoing advancement of global registrational Phase III clinical trials for orelabrutinib in collaboration with Zenas BioPharma.
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Zenas BioPharma presented new clinical data for obexelimab at the 6th International Symposium on IgG4-Related Disease. Phase 3 INDIGO open-label extension results showed sustained clinical activity with a 93% probability of remaining flare-free at 12 months, significantly reduced glucocorticoid toxicity compared to placebo, and positive vaccine responses during a treatment-free window. The data supports obexelimab's potential as a steroid-sparing B-cell inhibitor for long-term IgG4-RD management.